针对alpha-synuclein蛋白来治疗帕金森病,使用使用综合计算药物开发方法识别的新型抑制剂来治疗帕金森病
Arif Jamal Siddiqui1, Sadaf Jahan2, Juhi Saxena3
1Department of Biology, College of Science, University of Hail, P.O. Box 2440, 55476 Hail, Saudi Arabia.
In silico pharmacology
|November 10, 2025
概括
计算方法确定了四种抑制α-synuclein聚合的新型天然化合物,为帕金森病和相关的神经退行性疾病提供了潜在的新疗法.
科学领域:
- 神经科学是一个神经科学.
- 计算化学的计算化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔法-同核素 (α-syn) 聚合与像帕金森病 (PD) 这样的神经退行性疾病有关.
- 目前用于抑制α-syn聚合的药物发现工作面临临临床前挑战.
- α-syn中的遗传突变与家族形式的PD有关.
研究的目的:
- 使用计算方法识别能够抑制α-synuclein聚合的新型小分子.
- 探索天然产品库,寻找针对α-syn病理的潜在治疗剂.
主要方法:
- 使用了药模拟,分子对接和分子动力学模拟.
- ZINC天然产品库使用经过验证的药理模型进行了选.
- 使用MM/PBSA分析计算了绑定亲和和和自由能量.
主要成果:
- 确定了四种新的α-syn聚合的天然抑制剂,具有高的结合亲和力 (-9.43到-9.06 kcal/mol).
- 分子动力学模拟证实了蛋白质-配体复合物的稳定性 (RMSD < 2.5 Å).
- MM/PBSA计算显示了有利的结合自由能量 (-56.7到-49.2 kcal/mol).
结论:
- 该研究成功地确定了四种天然化合物作为α-synuclein聚合的强有力的抑制剂.
- 这些化合物显示出对帕金森病药物发现有前途的治疗潜力.
- 计算策略为识别α-syn聚合抑制剂提供了一个强大的框架.
更多相关视频
12:55High-throughput Functional Screening using a Homemade Dual-glow Luciferase Assay
Published on: June 1, 2014
24.4K
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
9.1K
相关概念视频
Parkinson's Disease: Treatment
954
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
954
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
